In July 2018, tisagenlecleucel (tisa-cel, Kymriah®), commercialized by Novartis, and axicabtagene ciloleucel (axi-cel, YESCARTA®), commercialized by Gilead, were the first CAR T-cell therapies to obtain a Marketing Authorization (MA) in France for the treatment of lymphoma.

The DESCAR-T registry was then created, at the request of the French Health Authorities, to collect data in order to consolidate knowledge on the efficacy and safety at both short- and long-term of all CAR T-cell therapies marketed in France, starting with axi-cel and tisa-cel.

A project was initiated by Prof. Emmanuel Bachy to compare the real-life efficacy and safety of these two treatments in diffuse large B-cell lymphoma (DLBCL).

Two groups of 209 patients, treated with one of the two CAR-Ts, were created from patients treated for lymphoma included in the DESCAR-T registry before July 2021. Patients were matched one by one on 14 parameters (including age, gender, specific diagnosis…) to generate two truly comparable populations.

The results of this analysis provide important insight to healthcare professionals, helping to choose of the best treatment option for each patient. This analysis is published in Nature Medicine.

To the patients that received CAR-T, if you would like more information about the treatment of your data in the DESCAR-T Registry, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.